At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Placebo 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of the Administration of Chlorogenic Acid on Glucemic Control, Insulin Secretion and Insulin Sensitivity in Patients With Impaired Glucose Tolerance
In Brief
A Phase 2 clinical trial evaluating Placebo and Chlorogenic acid for Impaired Glucose Tolerance. Completed, enrolled 30 participants across 1 site.
Detailed Summary
Chlorogenic acid has demonstrated promising effects in the treatment of glycemic control, obesity, dyslipidemia, insulin secretion, among others. The above mentioned findings show that Chlorogenic acid has an excellent potential for the control of glucose as well as insulin secretion and insulin sensitivity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImpaired Glucose Tolerance
CountriesMexico
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartSep 2015
First PostedDec 2015
Primary CompletionJan 2016
Study CompletionFeb 2016
TodayJul 2026
First PostedDec 3, 2015
Enrollment StartSep 1, 2015
Primary CompletionJan 1, 2016
Study CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.6 years ago
Interventions
Placebodrug
Placebo: 1200 mg per day for three months
Chlorogenic aciddrug
Chologenic acid: 1200 mg per day for three months